Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs
2017 (English)In: Journal of Pharmacy and Pharmacology (JPP), ISSN 0022-3573, E-ISSN 2042-7158, Vol. 69, no 2, 135-142 p.Article in journal (Refereed) Published
ObjectivesIn liver cancer treatment, lipiodol is used as a pharmaceutical excipient to improve delivery of the cytostatic drug doxorubicin (DOX). As DOX and its metabolite doxorubicinol (DOXol) cause serious off-target adverse effects, we investigated the effects of drug-free lipiodol or ciclosporin (CsA) on the tissue distribution (K-p) of DOX and DOXol in relevant pig tissues. MethodsFour treatment groups (TI-TIV) all received an intravenous DOX solution at 0 and 200 min. Before the second dose, the pigs received a portal vein infusion of saline (TI), lipiodol (TII), CsA (TIII) or lipiodol and CsA (TIV). After 6 h, the pigs were euthanised, and liver, kidney, heart and intestine samples were collected and analysed. Key findingsThe tissue DOX concentrations were highest in the kidney (TI-TIV). All the investigated tissues showed extensive DOX K-p. Lipiodol had no effect on the K-p of DOX to any of the tissues. However, the tissue concentrations of DOX were increased by CsA (in liver, kidney and intestine, P < 0.05). ConclusionLipiodol injected into the portal vein does not affect the tissue distribution of DOX and DOXol.
Place, publisher, year, edition, pages
2017. Vol. 69, no 2, 135-142 p.
ciclosporin, doxorubicin, K, (p), lipiodol, tissue distribution
Pharmacology and Toxicology
IdentifiersURN: urn:nbn:se:uu:diva-317962DOI: 10.1111/jphp.12665ISI: 000393174500003PubMedID: 27882559OAI: oai:DiVA.org:uu-317962DiVA: diva2:1086185